; nectin-4 cis-interacts with the prolactin receptor (Kitayama et al., 2016; ) and integrin α 6 β 4 (Pavlova et al., 2013) ; and Necl-5 cis-interacts with the PDGF receptor β (Amano et al., 2008; Ikeda et al., 2004; Kakunaga et al., 2004) , the vascular endothelial growth factor receptor (Kinugasa et al., 2012) and integrin α v β 3 (Minami et al., 2007) . These nectins and Necl-5 show the stimulatory effects on these receptors and the integrin. In contrast, Necl-2 cis-interacts with ErbB3 (Kawano, Ikeda, Kishimoto, Ogita, & Takai, 2009 ), ErbB4 (Yamada et al., 2013 ) and integrin α 6 β 4 (Mizutani et al., 2011) ; and Necl-4 cis-interacts with ErbB3 and integrin α 6 β 4 Mizutani et al., 2011; Sugiyama et al., 2013) . These Necls show inhibitory effects on these receptors and the integrin. By cis-interacting with these membrane receptors and integrins, nectins and Necls play roles not only in cell adhesion, but also in many other cell functions, such as cell polarization, morphogenesis, movement, proliferation, differentiation and survival (Mandai, Rikitake, Mori, & Takai, 2015) .
Necl-5 was originally identified as a poliovirus receptor (PVR)/CD155 in human (Koike et al., 1990; Mendelsohn, Wimmer, & Racaniello, 1989) and rodent Tage4 was originally identified as a product of a gene over-expressed in rodent colon carcinoma (Chadéneau, LeMoullac, & Denis, 1994) . PVR/ CD155 is also over-expressed in many human cancer cells (Gromeier, Lachmann, Rosenfeld, Gutin, & Wimmer, 2000; Masson et al., 2001) . We previously showed that Necl-5 forms a complex with the PDGF receptor β and integrin α v β 3 and that this complex is clustered and localized at peripheral ruffles over lamellipodia of the leading edge of the moving NIH3T3 cells in response to PDGF (Amano et al., 2008; Minami et al., 2007) . PDGF induces the activation of the small G protein Rap1 at the leading edge through the Necl-5-PDGF receptor β-integrin α v β 3 complex, followed by the activation of another small G protein, Rac1 (Takahashi et al., 2008) . Rac1 activated in this way promotes the formation of lamellipodia, peripheral ruffles and focal complexes at the leading edge that are necessary for directional cell movement (Miyata et al., 2009; Takai et al., 2008b) . Furthermore, Necl-5 is also involved in the regulation of cell proliferation in NIH3T3 cells . Necl-5 enhances the growth factor-induced activation of the Ras-Raf-MEK-ERK signaling pathway, causing up-and downregulation of cell cycle regulators, including cyclins D2 and E, and p27 kip1 , thereby shortening the period of the G1 phase of the cell cycle. The activation of the Ras-mediated signaling pathway is mediated through the inhibition of Necl-5-associated sprouty2 . Necl-5 interacts with sprouty2 and prevents sprouty2 from being phosphorylated on Tyr by Src. Thus, Necl-5 prolongs the growth factor-induced activation of cell proliferation signaling through the inhibition of sprouty2. In human umbilical vein cells, Necl-5 forms a complex with both the VEGF receptor and integrin α v β 3 and is essential for the VEGF-induced cell movement (Kinugasa et al., 2012) .
On the basis of these earlier observations, we investigated here the more detailed mechanisms for the cis-interaction of Necl-5 with the PDGF receptor β. We found that the third Ig-like domain of Necl-5 cis-interacted with the fifth Ig-like domain of the PDGF receptor β and that the recombinant protein of the third Ig-like domain of Necl-5 inhibited the cisinteraction of full-length Necl-5 with the PDGF receptor β and the PDGF-induced activation of ERK that was enhanced by Necl-5. We describe here the novel roles of the third Ig-like domain of Necl-5 and the fifth Ig-like domain of the PDGF receptor β in its signaling.
| RESULTS

| cis-Interaction of Necl-5 with the PDGF receptor β through the third Ig-like domain
We previously showed that Necl-5 cis-interacts with the PDGF receptor β through its extracellular region (Amano et al., 2008) , F I G U R E 1 cis-Interaction of Necl-5 with the PDGF receptor β through the third Ig-like domain. HEK293E cells were cotransfected with various combinations of the indicated plasmids. FLAG-Necl-5 or its mutants were immunoprecipitated using the anti-FLAG mAb, and the immunoprecipitated samples were subjected to Western blotting using the indicated Abs. Schematic diagram of Necl-5 mutants is also shown. IP, immunoprecipitation; IB, immunoblotting. The results are representative of three independent experiments | Genes to Cells
but the domains in the extracellular region of Necl-5 required for its cis-interaction with the PDGF receptor β were not determined. We first examined which Ig-like domain of Necl-5 is required for the cis-interaction with the PDGF receptor β. For this purpose, two mutants of FLAG-tagged Necl-5, one that lacks the first Ig-like domain and the cytoplasmic region of Necl-5 (FLAGNecl-5-ΔIg1ΔCP) and one that lacks the first and second Ig-like domains and the cytoplasmic region of Necl-5 (FLAG-Necl-5-Δ(Ig1-Ig2)ΔCP), were prepared. HA-tagged PDGF receptor β (PDGFRβ-FL-HA) was co-expressed with FLAG-tagged full-length Necl-5 (FLAG-Necl-5-FL) or one of the mutants of Necl-5. When FLAG-Necl-5-FL or FLAG-tagged Necl-5 mutant that lacks the cytoplasmic region of Necl-5 (FLAG-Necl-5-ΔCP) was immunoprecipitated using an anti-FLAG monoclonal antibody (mAb), PDGFRβ-FL-HA was co-immunoprecipitated with FLAG-Necl-5-FL or FLAG-Necl-5-ΔCP (Figure 1 ). This was consistent with the previous observation (Amano et al., 2008) . When FLAG-Necl-5-ΔIg1ΔCP or FLAG-Necl-5-Δ(Ig1-Ig2) ΔCP was immunoprecipitated using the anti-FLAG mAb, PDGFRβ-FL-HA was co-immunoprecipitated with FLAG-Necl-5-ΔIg1ΔCP or FLAG-Necl-5-Δ(Ig1-Ig2)ΔCP. These results indicate that Necl-5 cis-interacts with the PDGF receptor β through the third Ig-like domain, although it cannot be concluded that other Ig-like domains are not involved in this cis-interaction.
| cis-Interaction of the PDGF receptor β with Necl-5 through the fifth Ig-like domain
We next attempted to determine the Necl-5-interacting domain of the PDGF receptor β. For this purpose, HA-tagged mutants of the PDGF receptor β, of which the Ig-like domains were deleted in a stepwise manner, were prepared (PDGFRβ-ΔD1-HA, a mutant lacking the first Ig-like domain (D1) of the PDGF receptor β; PDGFRβ-Δ(D1-D2)-HA, a mutant lacking the D1 domain and the second Ig-like domain (D2) of the PDGF receptor β; PDGFRβ-Δ(D1-D3)-HA, a mutant lacking the D1 domain, the D2 domain and the third Ig-like domain (D3) of the PDGF receptor β; and PDGFRβ-Δ(D1-D4)-HA, a mutant lacking the D1 domain, the D2 domain, the D3 domain and the fourth Ig-like domain (D4) of the PDGF receptor β). FLAG-Necl-5-FL was co-expressed in HEK293E cells with full-length PDGF receptor β or one of the various mutants of the PDGF receptor β. When FLAG-Necl-5 was immunoprecipitated using the anti-FLAG mAb, all the mutants of the PDGF receptor β were co-immunoprecipitated with FLAG-Necl-5-FL (Figure 2 ). These results indicate that the PDGF receptor β cis-interacts with Necl-5 through the fifth Ig-like domain, although it cannot be concluded that other Ig-like domains are not involved in this cis-interaction.
| Inhibition of the cis-interaction of
Necl-5 with the PDGF receptor β by the recombinant protein of Necl-5
We next examined whether the recombinant protein of the third Ig-like domain of Necl-5 shows an inhibitory effect on the cis-interaction of full-length Necl-5 with the PDGF receptor β as schematically shown in Figure 3a , because this domain was a minimal interacting region with the PDGF receptor β. FLAG-tagged extracellular region of Necl-5 F I G U R E 2 cis-Interaction of the PDGF receptor β with Necl-5 through the fifth Ig-like domain. HEK293E cells were cotransfected with various combinations of the indicated plasmids. FLAG-Necl-5 was immunoprecipitated using the anti-FLAG mAb, and the immunoprecipitated samples were subjected to Western blotting using the indicated Abs. Schematic diagram of the PDGF receptor β fragments is also shown. IP, immunoprecipitation; IB, immunoblotting. The results are representative of three independent experiments Genes to Cells UEDA Et Al.
(FLAG-Necl-5-EC), FLAG-tagged third Ig-like domain of Necl-5 (FLAG-Necl-5-Ig3-V5-His) and Target-tagged extracellular region of the PDGF receptor β (PDGFRβ-EC-Target) were expressed in HEK293E cells and affinity-purified. PDGFRβ-EC-Target was captured on anti-Target-Abconjugated beads, and the fixed amount of FLAG-Necl-5-EC was incubated with or without FLAG-Necl-5-Ig3-V5-His. The amount of FLAG-Necl-5-EC coprecipitated with PDGFRβ EC-Target was reduced in the presence of FLAG-Necl-5-Ig3-V5-His (Figure 3b ). This result indicates that the recombinant protein of the third Ig-like domain of Necl-5 inhibits the cisinteraction of full-length Necl-5 with the PDGF receptor β in a competitive manner, and supports the above conclusion that Necl-5 indeed cis-interacts with the PDGF receptor β through the third Ig-like domain.
| Inhibition of the PDGF-induced activation of ERK by the recombinant protein of the third Ig-like domain of Necl-5
We next examined by measuring the phosphorylation of the PDGF receptor β and ERK to determine whether the recombinant protein of the third Ig-like domain of Necl-5 inhibits the PDGF-induced phosphorylation of the PDGF receptor β and ERK in NIH3T3 cells. When the cells were stimulated with PDGF alone, the phosphorylation of both the PDGF receptor β and ERK was observed in a timedependent manner ( Figure 4A , Ba, Bb). When the cells were stimulated with PDGF in the presence of FLAGNecl-5-Ig3-V5-His, the phosphorylation of ERK, but not the PDGF receptor β, was inhibited ( Figure 4A , Ba, Bb).
These results were consistent with the previous observation that Necl-5 does not affect the PDGF-induced tyrosine phosphorylation of the PDGF receptor β and indicate that the cis-interaction of Necl-5 with the PDGF receptor β through the third Ig-like domain is required for the PDGF-induced activation of ERK that is enhanced by endogenous Necl-5, but not the PDGFinduced tyrosine phosphorylation of the PDGF receptor β.
| Requirement of the posttranslational modification of Necl-5 for enhancing the PDGF-induced activation of ERK
We finally examined whether a synthetic peptide corresponding to the third Ig-like domain of Necl-5 also shows the inhibitory effect on the PDGF-induced phosphorylation of ERK. For this purpose, we obtained the synthetic peptide, which contains the third Ig-like domain of Necl-5 (amino acids 267-316). When the cells were stimulated with PDGF in the presence of the peptide, similar levels of the phosphorylation of the PDGF receptor β and ERK were observed, compared with those in the cells simulated with PDGF alone ( Figure 5 ). These results indicate that the synthetic peptide of the third Ig-like domain of Necl-5 does not inhibit the PDGF-induced phosphorylation of ERK that is enhanced by endogenous Necl-5 and suggest that proper posttranslational modification of the third Ig-like domain might be required for the cis-interaction of Necl-5 with the PDGF receptor β and the enhancement of the PDGF receptor β signaling by Necl-5. 
| DISCUSSION
We showed here that the third Ig-like domain of Necl-5 mediated its cis-interaction with the PDGF receptor β. Nectins and Necls have three Ig-like domains in their extracellular regions and play roles not only in cell adhesion, but also in many other cell functions, such as cell polarization, morphogenesis, movement, proliferation, differentiation and survival (Mandai et al., 2015) . Two nectin molecules at the surface of the same cell first form cis-dimers, followed by transinteraction by the cis-dimers on opposing cells (Miyahara et al., 2000) . The first Ig-like domain of the extracellular region of nectin-1 is necessary for the formation of transdimers, but not for cis-dimers, whereas the second Ig-like domain contributes to the formation of cis-dimers (Momose et al., 2002; Yasumi, Shimizu, Honda, Takeuchi, & Takai, 2003) . Measurements from intermolecular force microscopy showed that nectins have another adhesion state in addition to the adhesion mediated through the interaction between the first Ig-like domains (Tsukasaki et al., 2007) . In this adhesion state, the first, second and third Ig-like domains interact in trans with the third, second and first Ig-like domains of another nectin molecule, respectively, in a zipper-like fashion, although the adhesion activity of this state is lower than that of the adhesion mediated through the interaction between the first Ig-like domains. In addition, another function of the third Ig-like domain of nectins was recently shown. It was reported that the third Ig-like domain of nectin-1 could directly bind and activate the FGF receptor, thereby inducing neurite outgrowth and promoting neuronal survival (Bojesen et al., 2012) . Our recent study also showed that the third Iglike domain of nectin-4 cis-interacts with the prolactin receptor and stimulates the prolactin-induced signaling and that the third Ig-like domain of Necl-4 cisinteracts with ErbB3 and inhibits the ligand-induced dimerization of ErbB3 with ErbB2 . These results suggest that the third Ig-like domain of nectins or Genes to Cells
Necls is important for determining their specificity for its cisinteraction with the receptors. We did not investigate here the necessity of the third Ig-like domain of Necl-5 for its cis-interaction with the PDGF receptor β, but we previously showed that the third Ig-like domain of Necl-4 is necessary and sufficient for its inhibitory effects on the heregulininduced dimerization of ErbB3 with ErbB2 and phosphorylation of ErbB3 . It is likely from these previous and present results that the third Ig-like domain of Necl-5 is necessary and sufficient for its cis-interaction with the PDGF receptor β and the regulation of the PDGF receptor β signaling.
We also showed here that the fifth Ig-like domain of the PDGF receptor β mediated its cis-interaction with Necl-5 and that this cis-interaction played a role in the PDGF-induced activation of ERK. The PDGF receptor β regulates a variety of cell functions, including cell proliferation, differentiation, migration and survival, and its genetic mutation causes maltransformation of cells, leading to tumorigenesis (Heldin, 2013) . The PDGF receptor β belongs to class III receptor tyrosine kinases, which include KIT, CSF1R/FMS and FLT3. The PDGF receptor β has five Ig-like domains (the D1, D2, D3, D4 and D5 domains) in its extracellular region and upon binding of PDGF to the D1, D2 and D3 domains causes the dimerization of the receptor and activation of its tyrosine-kinase activity, eventually causing the activation of its downstream signaling molecules, such as Ras, phospholipase C and PI3-kinase. A homotypic contact between the D4 domains is also involved in this PDGF-induced dimerization, but the role of the D5 domain remained unknown. Recently, it was shown that the D5 domain of the PDGF receptor β also forms a homotypic contact as determined by negative-stain electron microscopy (Chen, Unger, & He, 2015) . Similarly, homotypic contact of the D5 domain was observed in the stem cell factor receptor KIT (Opatowsky et al., 2014) . In contrast, M-CSF1-bound CSF1R dimers showed a large 65-Å separation between the neighboring D5 domains (Elegheert et al., 2011) . These results suggest that the receptor homodimerization mechanism upon binding its ligand is different even in the same class III receptor tyrosine kinases. Our present study showed that the D5 domain of the PDGF receptor β was involved in its cis-interaction with Necl-5, although the detailed mechanism by which the third Ig-like domain of Necl-5 cis-interacts with the fifth Ig-like domain of the PDGF receptor β to enhance the ligand-induced dimerization of the PDGF receptor β remains unclear (Figure 6 ). Crystallographic studies on the Necl-5-PDGF receptor β heterodimer are needed to address this matter.
We previously showed that a Necl-5 mutant, in which its cytoplasmic region was deleted, inhibited the cell motility and serum-induced proliferation of NIH3T3 cells Kakunaga et al., 2004 ). The precise role of the mutant remains elusive, but presumably the mutant inhibited the cis-interaction of endogenous Necl-5 with the PDGF receptor β. Consistent with these earlier observations, we showed here that the recombinant protein of the third Ig-like domain of Necl-5, which was purified from HEK293E cells, inhibited the cis-interaction of Necl-5 with the PDGF receptor β and the PDGF-induced activation of ERK. However, the synthetic peptide did not inhibit the PDGF-induced activation of ERK. There are two major differences between the recombinant protein and the synthetic peptide of the third Ig-like domain of Necl-5. One difference is that whether it is glycosylated or not. Glycosylation, such as N-glycosylation, O-glycosylation or sialylation, is one of the important posttranslational modifications of proteins, and approximately 50% of all proteins are glycosylated (Apweiler, Hermjakob, & Sharon, 1999) . PVR/CD155, a human homologue of mouse Necl-5, has three potential N-glycosylation sites in the third Ig-like domain (He et al., 2003) . It was reported that the Necl family members show an upward mobility shift by N-glycosylation, although Necl-5 was not investigated (Fogel et al., 2007) . It was also reported that Necl-2 is sialylated by ST6GAL1 (Minami et al., 2013) or polysialylated by ST8SiaI and ST8SiaIV (Galuska et al., 2010) . It is possible that specific glycosylation(s) in the third Ig-like domain of Necl-5 is required for its cis-interaction with the PDGF receptor β and for inhibiting the cis-interaction of Necl-5 with the PDGF receptor β in NIH3T3 cells. The other difference is that whether it has additional amino acids at both ends of the cysteine residues, which form disulfide bond, or not. The recombinant protein of the third Ig-like domain has 15 and 30 amino acids at both ends of the cysteine residues, respectively, but the synthetic peptide has no amino acid at the both ends of the cysteine residues. It is possible that the additional amino acids are required for proper folding of the third Ig-like domain of Necl-5; thereby, the synthetic peptide is not properly folded for interacting with the PDGF receptor β. Further detailed investigation is required to address these issues.
Targeting the PDGF-induced signaling pathways is considered to be an attractive approach for cancer treatment, because the hyperactivation of the PDGF-induced signaling is involved not only in growth stimulation of tumor cells, but also in functional regulations of tumor stroma fibroblasts and tumor angiogenesis (Heldin, Lennartsson, & Westermark, 2017; Pietras, Sjöblom, Rubin, Heldin, & Östman, 2003) . Indeed, several inhibitors for the PDGF-induced signaling pathways, including low molecular weight inhibitors, humanized mAbs or DNA aptamers, are being developed or in clinical use. The hyperactivation of the PDGF-induced signaling pathways is mainly due to an over-expression of PDGF or the PDGF receptor, although there are a few tumor types in which mutations in the genes for PDGF isoforms or receptors drive tumor development (Heldin et al., 2017) . It is possible that the over-expressed PDGF receptor β increases an opportunity to form a complex with endogenous Necl-5, thereby enhancing | Genes to Cells UEDA Et Al.
the Necl-5-PDGF receptor β-induced signaling. We previously showed that Necl-5 and sprouty2 cooperatively regulate the PDGF-induced Ras signaling . Sprouty is a negative regulator of the growth factor-induced signaling and is tyrosine-phosphorylated by c-Src, of which activation is induced by many growth factors through their respective receptors (Gross, Bassit, Benezra, & Licht, 2001; Hanafusa, Torii, Yasunaga, & Nishida, 2002; Li, Brunton, Burgar, Wheldon, & Heath, 2004; Mason et al., 2004) . The physical interaction of sprouty2 with Necl-5 prevents sprouty2 from being tyrosine-phosphorylated by c-Src, thereby reducing the inhibitory effect of sprouty2 on the PDGF-induced Ras signaling ( Figure 6 ) . Given the fact that the hyperactivation of the Src or Ras signaling is frequently observed in cancer cells and that the expression of sprouty2 is down-regulated in breast or prostate cancers (Lo et al., 2004; McKie et al., 2005; Tsavachidou et al., 2004) , dysfunction of the inhibitory effect of sprouty2 on the Ras-ERK signaling is thought to contribute to the progression of cancers. We showed here that the recombinant protein of the third Ig-like domain of Necl-5 inhibited the cis-interaction of endogenous Necl-5 with the endogenous PDGF receptor β in NIH3T3 cells, resulting in the inhibition of the PDGF-induced activation of ERK that was enhanced by endogenous Necl-5. Inhibition of the cis-interaction of Necl-5 with the PDGF receptor β might represent a novel target for cancer treatment, and our findings of this study may contribute to the development of novel anticancer drugs.
| EXPERIMENTAL PROCEDURES
| Plasmid construction
pCAGI-Puro-FLAG-Necl-5 was prepared as described (Ikeda et al., 2003) . pCAGI-Puro-FLAG-Necl-5-ΔCP (amino acids 30-374), pCAGI-Puro-FLAG-Necl-5-ΔIg1ΔCP (amino acids 132-374) and pCAGI-Puro-FLAGNecl-5-Δ(Ig1-Ig2)ΔCP (amino acids 251-374) were constructed by PCR using pCAGI-Puro-FLAG-Necl-5 as a template. A cDNA fragment of the third Ig-like domain of Necl-5 (amino acids 251-347) was amplified by PCR and inserted into pcDNA3.1/V5-His TOPO vector (Thermo Fisher Scientific, Waltham, MA). The cDNA fragment of the third Ig-like domain of Necl-5 with V5 and His tag sequences was further amplified by PCR and inserted into pCAGI-Puro vector. pCAGI-Puro-PDGFRβ-HA (amino acids 33-1,106), pCAGI-Puro-PDGFRβ-ΔD1-HA (amino acids 125-1,106), pCAGI-Puro-PDGFRβ-Δ(D1-D2)-HA (amino acids 213-1,106), pCAGI-Puro-PDGFRβ-Δ(D1-D3)-HA (amino acids 314-1,106) and pCAGI-Puro-PDGFRβ-Δ(D1-D4)-HA (amino acids 423-1,106) were constructed by PCR using pCAGI-Puro-PDGFRβ-HA as a template. A cDNA fragment of the extracellular region of the PDGF receptor β (amino acids 33-553) was amplified by PCR and inserted into pC-Target-IRES-Puro vector, which was constructed by removing the FLAG-tag sequence from pFLAG-CMV1 (Sigma-Aldrich), followed by inserting Target-tag and IRES-Puro sequences. Preprotrypsin signal peptide sequence was inserted into the plasmids of all the Necl-5 and the PDGF receptor β mutants in their N-terminus.
| Abs and reagents
Mouse anti-FLAG mAb (for immunoprecipitation, F3165; Sigma-Aldrich, St. Louis, MO), rabbit anti-FLAG polyclonal antibody (pAb) (for immunoblotting, F7425; Sigma-Aldrich), mouse anti-HA mAb (MMS-101P; BioLegend, San Diego, CA), mouse anti-TARGETtag mAb (Wako Pure Chemical Industries, Ltd., Osaka, Japan), rabbit anti-PDGF receptor β (958) pAb (sc-432; Santa Cruz Biotechnology Inc., Santa Cruz, CA), rabbit anti-phospho-PDGF receptor β (Tyr857) pAb (sc-12907; Santa Cruz Biotechnology Inc.), rabbit anti-ERK1/2 pAb (#9102; Cell Signaling Technology, Danvers, MA) and mouse anti-phospho-ERK1/2 (Thr202/Tyr204) mAb (clone E10, #9106; Cell Signaling Technology) were purchased from indicated suppliers. Horseradish peroxidase (HRP)-conjugated secondary Abs for anti-mouse and antirabbit IgG were purchased from GE Healthcare (Little Chalfont, UK). Fatty acid-free bovine serum albumin (BSA) was purchased from MP Biomedicals (Solon, OH). A trypsin inhibitor and Phosphatase Inhibitor Cocktail were purchased from Sigma-Aldrich. The synthetic peptide of the third Ig-like domain of Necl-5 corresponding to amino acids 267-316 was purchased from Cosmo Bio (Tokyo, Japan).
| Protein purification
For the purification of FLAG-tagged extracellular region of Necl-5 (FLAG-Necl-5-EC, amino acids 30-347), FLAG-tagged third Ig-like domain of Necl-5 (FLAG-Necl-5-Ig3-V5-His, amino acids 251-347) and Target-tagged extracellular region of the PDGF receptor β (PDGFRβ-ECTarget, amino acids 33-527), HEK293E cells were transfected with the indicated plasmids. After the selection of the transfected cells by puromycin, the cells were cultured in a serum-free media (SAFC Biosciences Inc., Lenexa, KS). The secreted FLAG-tagged proteins were purified from the conditioned media by DDDDK-Ab-conjugated beads (MBL International), or the secreted Target-tagged proteins were purified from the conditioned media by Anti-TARGET tag Antibody Beads (Wako Pure Chemical Industries, Ltd.). The DDDDK-peptide-eluted FLAGtagged proteins or Target-peptide-eluted Target-tagged proteins were ultrafiltered several times for dialysis and concentration using Amicon Ultra-4 Centrifugal Filter Unit (nominal molecular weight limit 3 kDa; Merck Millipore, Billerica, MA).
| Cell culture and transfection
HEK293E cells were maintained in Dulbecco's modified Eagle's medium (DMEM) supplemented with 10% fetal bovine serum, 100 U/ml penicillin and 100 μg/ml streptomycin and cultured at 5% CO 2 at 37°C. NIH3T3 cells were maintained in DMEM supplemented with 10% fetal calf serum, 100 U/ml penicillin and 100 μg/ml streptomycin and cultured at 5% CO 2 at 37°C.
| Co-immunoprecipitation assay
HEK293E cells were cotransfected with various combinations of the indicated plasmids using Lipofectamine 3000 reagent (Thermo Fisher Scientific) according to the manufacturer's instructions and cultured for 48 hr. The cells were detached with 0.05% trypsin and 0.53 mM EDTA and then treated with a trypsin inhibitor. The cells were cultured in suspension with DMEM containing 0.5% fatty acid-free BSA for 30 min, collected by centrifugation and lysed with a lysis buffer (20 mM Tris-HCl, pH 8.0, 150 mM NaCl, 1 mM CaCl 2 , 1 mM MgCl 2 , 10% glycerol, 1% Nonidet P-40, 10 mM NaF, 1 mM Na 3 VO 4 , 10 μg/ml leupeptin, 2 μg/ml aprotinin and Phosphatase Inhibitor Cocktail 3). The lysates were rotated at 4°C for 30 min and subjected to centrifugation at 12,000 g for 15 min. The supernatant was incubated with the anti-FLAG mAb-conjugated Dynabeads Protein G (Veritas, Tokyo, Japan) at 4°C for 2 hr. After the beads were extensively washed with a wash buffer (phosphate-buffered saline (PBS) plus 0.02% Tween-20, 1 mM CaCl 2 and 1 mM MgCl 2 ), bound proteins were eluted by DDDDK peptide (MBL) and subjected to SDS-PAGE, followed by Western blotting using the indicated Abs.
| Western blotting
The samples separated on SDS-PAGE were transferred to poly(vinylidene difluoride) membranes (Merck Millipore). After being blocked with 5% skim milk in Tris-buffered saline plus 0.05% Tween-20, the membranes were incubated with the indicated Abs. After being washed with Tris-buffered saline plus 0.05% Tween-20 three times, the membranes were incubated with HRP-conjugated anti-rabbit or anti-mouse IgG Ab. The signals for the proteins were detected using Immobilon Western Chemiluminescent HRP Substrate (Merck Millipore). BSA for 24 hr and then stimulated by DMEM containing 3 ng/ ml PDGF (Wako Pure Chemical Industries, Ltd.) for the indicated time periods. To analyze the effects of the third Ig-like domain of Necl-5, 1 μM FLAG-Necl-5-Ig3-V5-His or the synthetic peptide was added. The cells were washed with ice-cold PBS three times and lysed with a RIPA buffer (20 mM Tris-HCl, pH 7.5, 1% Nonidet P-40, 0.5% sodium deoxycholate, 0.1% SDS, 10% glycerol, 137 mM NaCl, 1 mM CaCl 2 , 1 mM MgCl 2 , 50 mM NaF, 1 mM Na 3 VO 4 , 10 μg/ml leupeptin, 2 μg/ml aprotinin, 10 μM APMSF and Phosphatase Inhibitor Cocktail 3). The lysates were then boiled in an SDS sample buffer (60 mM Tris-HCl, pH 6.7, 3% SDS, 2% 2-mercaptoethanol and 5% glycerol) for 5 min and subjected to SDS-PAGE, followed by Western blotting using the indicated Abs.
| Competitive interaction assay
The competitive interaction assay between the extracellular region of Necl-5 and the third Ig-like domain of Necl-5 with the PDGF receptor β was carried out using FLAG-Necl-5-EC and PDGFRβ-EC-Target by adding FLAG-Necl-5-Ig3-V5-His. Anti-TARGET tag Antibody Beads conjugated with PDGFRβ-EC-Target were mixed with FLAG-Necl-5-EC in the presence or absence of 10 μM FLAG-Necl-5-Ig3-V5-His and incubated in PBS plus 0.02% Tween-20 for 16 hr. The beads were washed three times with PBS plus 0.02% Tween-20, and the bound proteins were eluted with the SDS sample buffer by boiling for 5 min. The samples were subjected to SDS-PAGE, followed by Western blotting using the indicated Abs.
| Statistical analysis
The data are reported as means ± SEM. Statistical analysis of the difference mean values was carried out with the twotailed Student's t test.
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